Tonix Pharmaceuticals Holding Corp. announced that its Phase 3 RESILIENT study of TONMYA (cyclobenzaprine HCl sublingual tablets) met its primary endpoint, showing a statistically significant reduction in weekly average pain scores versus placebo at 14 weeks. The 456‑patient, double‑blind, placebo‑controlled trial enrolled adults who met the 2016 American College of Rheumatology criteria for fibromyalgia and reported a p‑value of less than 0.0001 with an effect size of 0.38.
Secondary endpoints also improved, with significant reductions in sleep disturbance, fatigue, and both the Symptoms and Function domains of the Fibromyalgia Impact Questionnaire‑Revised, each achieving p‑values below 0.001. These findings confirm TONMYA’s ability to address the sleep‑related pain that is a hallmark of fibromyalgia and support its positioning as a first‑in‑class, non‑opioid therapy.
Safety data were favorable; the drug was well tolerated, with a 6.1% adverse‑event–related discontinuation rate compared to 3.5% for placebo. The most common adverse events were mild, self‑limited oral cavity reactions that rarely led to study withdrawal, underscoring the tolerability advantage of the sublingual formulation.
Financially, Tonix’s commercial launch of TONMYA in November 2025 has not yet translated into significant revenue growth, with the company reporting $10.3 million in revenue and negative operating and net margins of –932.42% and –963.39%, respectively. The positive Phase 3 data are therefore a critical milestone that could unlock future sales and improve the company’s cash‑flow profile, but the company remains in a high‑burn, low‑margin phase as it scales the product.
Market reaction to the presentation was muted, with the company’s shares closing slightly lower on the day of the summit and a modest uptick in pre‑market trading the following day. Analysts noted the clinical success but emphasized the need for robust commercial execution and the challenge of converting early sales into sustained revenue growth.
CEO Seth Lederman highlighted the significance of the data, stating that TONMYA “provides a centrally‑acting, differentiated non‑opioid treatment that addresses a critical unmet need in fibromyalgia patients.” Chief Medical Officer Dr. Gregory Sullivan added that the sublingual formulation “optimizes parent‑drug exposure during sleep while limiting daytime metabolite levels,” potentially improving adherence and patient outcomes. The company remains focused on scaling production, expanding market access, and leveraging its pipeline to diversify revenue streams.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.